Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery

(PresseBox) ( Dresden, )
Cenix BioScience GmbH (Dresden), a leading specialist in advanced RNA interference (RNAi)-based research services today announced that they have signed a research agreement with Regulus Therapeutics LLC to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.

Cenix will apply its well-established expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic potential in the area of immunology and inflammation.

"Following the long-standing relationship and mutual respect shared with several key members of the starting team at Regulus, we at Cenix are very much looking forward to working together to drive this ground-breaking discovery program forward" said Dr.Christophe Echeverri, CEO/CSO of Cenix.

"Regulus is committed to discovering and developing novel microRNA-targeted therapeutics and adding to a large and growing body of knowledge on how individual microRNAs function within the cell," said Peter S. Linsley, Ph.D. CSO of Regulus. "We look forward to working collaboratively with Cenix to identify interesting microRNA-targeted drug candidates."

No further terms of the agreement were released.

About Regulus Therapeutics LLC

Regulus Therapeutics LLC is a biopharmaceutical company formed to discover, develop, and commercialize microRNA (miRNA) therapeutics. Regulus aspires to translate one of the most important new discoveries in biology into a novel new approach for innovative medicine and to build the leading miRNA company. Created as a joint venture by Alnylam Pharmaceuticals and Isis Pharmaceuticals, Regulus benefits from oligonucleotide drug discovery expertise, an established technology, and a broad intellectual property estate created and consolidated by its parent companies for the development and commercialization of miRNA therapeutics.Regulus' patent estate includes over 600 patents and more than 300 pending patent applications, pertaining primarily to chemical modifications of oligonucleotides targeting miRNA for therapeutic applications. In addition, Regulus has collaborations with academic researchers to build on the company's understanding of more than 60 miRNAs. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to explore miRNA therapeutics for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
Regulus, founded in September 2007, maintains facilities in Carlsbad, California. For more information, visit www.regulusrx.com.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.